Multicenter Retrospective Study to Evaluate Docetaxel plus Ramucirumab after Combination Therapy with PD-1 Inhibitor and Chemotherapyin Advanced Non-Small Cell Lung Cancer
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000042333
- Brief Summary
The ORR and DCR of RD were 28.8% (95% CI, 23.7-34.4) and 69.8% (95% CI, 64.1-75.0), respectively. Median PFS was 4.1 months (95% CI, 3.5-4.6); median OS was 11.6 months (95% CI, 9.9-13.9). Univariate and multivariate Cox regression analysis of OS showed that bone metastases at diagnosis, poor PS (2-3), and non-adenocarcinoma were independent poor prognostic factors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 288
Inclusion Criteria
Not provided
Exclusion Criteria
Patients judged by the principal investigator of each institution to be inappropriate for registration
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Best response Last date of survival confirmation/date of death
- Secondary Outcome Measures
Name Time Method